Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atara Biotherapeutics strengthens financial position and advances clinical milestones

Atara Biotherapeutics is strategically positioned to drive growth through financial stability, pipeline advancements, and operational efficiency.
Despite workforce reductions, the company's focus on key clinical milestones and regulatory milestones bodes well for future revenue potential.
Navigating challenges in workforce restructuring and regulatory hurdles, Atara remains focused on leveraging opportunities in CAR-T therapies and autoimmune diseases.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy for the treatme.

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST /.

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosu.

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal Phase 3 ALLEL.

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share i.

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company's 2023 accomplishments across strategic priorities and key upcoming milestones at the 42nd Annual J.P. Morgan Healthc.

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, Cal.

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-ce.

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. Findings support ATA3431 advancement into clinical testing, in.

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara's common stock to three newly hired employees. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the.

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving.

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.

Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST. A live.

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Oblong

Seelos Therapeutics

Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more.

Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List

Blade Air Mobility

Fortress Biotech

FTC Solar

Gossamer Bio Inc

GrowGeneration Corp

iHeartMedia

Ondas Holdings

PureCycle Technologies

Ring Energy

Xeris Biopharma Holdings

Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.

11 Top Penny Stocks To Buy Now According To Insiders

Penny stocks are often priced under $5 per share. They attract traders seeking big gains.

5 Penny Stocks To Buy Now According To Insiders

Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring, tab-cel deal with Pierre Fabre, and lower future R&D expenses (considering failure of ATA188 and prioritization of ATA3219 and ATA3431) have extended cash runaway beyond Q3 2025. Pierre Fabre will not only take over all costs associated with tab-cel but will also pay ATRA $30M upfront, as well as $100M in regulatory milestone payments through BLA approval.

Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. ES.

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Atara Biotherapeutics (NASDAQ: ATRA ) stock is falling hard on Thursday after the therapeutic company announced results from a Phase 2 clinical trial. The bad news for ATRA stockholders is the company's Phase 2 clinical trial of ATA188 as a treatment for non-active progressive multiple sclerosis failed to meet its primary endpoint.

Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today?

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS). The study did not meet the primary endpoint of confirmed disability improvement (CDI) by exp.

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics' Third Quarter 2023 Financial Results Conference Call.

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported recent business highlights including an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel®), financial results for the third quarter 2023, and key upcoming catalysts. “We.

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.

Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel®) in the U.S. Following productive discussions between Atara and the U.S. Food and Drug Administration (FDA), the FDA and Atara.

News for Atara Biotherapeutics Stock (ATRA)